---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-24-000007"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:15:57.819100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Codexis reports Q4 net loss $7.2M; FY2023 net loss $76.2M; guides 2024 product rev $38-42M ex-PAXLOVID

## Summary
- Q4 net loss $7.2M ($0.10/sh); FY2023 net loss $76.2M ($1.12/sh). Excl PAXLOVID & impairment, adj FY net loss $50.8M ($0.74/sh).
- FY2023 total rev $70.1M (incl PAXLOVID); ex-PAXLOVID rev $62.0M (-2% YoY). Product rev ex-PAXLOVID $34.8M (-16% YoY).
- Q4 total rev $26.6M; ex-PAXLOVID rev $18.4M (+42% YoY). R&D rev $8.5M.
- 2024 guidance: Product rev $38-42M ex-PAXLOVID, R&D rev $18-22M, product GM 58-63%. Cash runway to positive CF around end-2026.
- Recent deals: Nestlé up to $45M milestones for CDX-7108; $40M Innovatus loan; Roche exclusive license for dsDNA ligase.

## SEC filing metadata
- accession: 0001200375-24-000007
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000007/0001200375-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000007/cdxs-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-24-000007
- JSON: https://secwatch.observer/filing/0001200375-24-000007.json
- Plain text: https://secwatch.observer/filing/0001200375-24-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.